Boston, MA 02\/19\/2014 (wallstreetpr) –\u00a0Chelsea Therapeutics International Ltd (NASDAQ:CHTP) <\/b>received the best news it could have wished for,with the approval of its Northera drug that has been developed to treat neurogenic ortostatic hypotension, which is a rare disease known to cause a drop in blood pressure upon standing. The news could not have come at a better time as the company stock were up beat in Tuesday trading session soaring by highs of 35% to highs of $6.70 a share.<\/p>\n
The disease upon causing low blood pressure is known to make patients feel dizzy with lots of fatigue, blurry vision, general bodyweakness and increased head and neck pain. The disease is common with people suffering illnesses such as Parkinson disease, diabetic neuropathy as well as multiple system atrophy.<\/p>\n
\u00a0FDA announcement<\/b><\/p>\n
FDA in its announcement reiterated that it is approving Northera under accelerated approval program which gives it the power to approve a drug that has the capability of treating serious diseases based on clinical data. This program is essentially beneficial to patients suffering from such conditions as it allows them to use a drug while awaiting post approval clinical trials aimed at verifying a drugs clinical benefit.<\/p>\n
Northera on the other hand comes with a warning sign to physicians, warning them on the possibility of increased blood pressure if a patient takes the pill and lies down. This is a common problem with many patients facing autonomic failure and is known to lead to strokes in some patients.<\/p>\n
Chelsea Therapeutics International Ltd (NASDAQ:CHTP)<\/b> Chief executive officer Joseph G Oliveto was quick to point out, that the approval was a good gesture from FDA and marks an extraordinary achievement on the side of the company as it strives to provide better medications that have minimal health repercussions to the consumers. Chelsea Therapeutics plans to take the pill to more patients across the U.S. suffering from NOH.<\/p>\n
NOH is an autonomic nervous system disorder caused by the failure of the body to produce enough norepinephrine whenever affected patients are standing. In this case affected persons fail to maintain enough blood pressure for supplying enough blood to the brain thus the result of common symptoms of Laziness, Dizziness and blurry vision. The illness is estimated to affect a total of between 80,000 to 150,000 individuals in the U.S. alone.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 02\/19\/2014 (wallstreetpr) –\u00a0Chelsea Therapeutics International Ltd (NASDAQ:CHTP) received the best news it could have wished for,with the approval of its Northera drug that […]<\/p>\n","protected":false},"author":3,"featured_media":15606,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2944,2439],"stock_ticker":[],"class_list":["post-15605","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-chelsea-therapeutics-international-ltd-nasdaqchtp","tag-nasdaqchtp","entry"],"acf":[],"yoast_head":"\n